David Carter's questions to Bio Rad Laboratories Inc (BIO) leadership • Q2 2025
Question
David Carter, on for Connor McNamara at RBC, asked for confirmation of the implied organic growth ramp in the second half of the year and questioned the initial customer response to the new Continuum ddPCR platform, particularly from lower-throughput labs.
Answer
Executive VP & CFO Roop Lakkaraju confirmed the implied organic growth progression for the second half was accurate. President & COO Jonathan DiVincenzo explained that the Q4 ramp is partly due to an easier comparison from the prior year when China's reimbursement changes first hit. Regarding the Continuum platform, DiVincenzo stated it is still too early for direct user feedback but highlighted its flexibility for both single-sample and 96-well plate runs is a key advantage being promoted to customers.